Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 39.59 USD 1.67% Market Closed
Market Cap: 3.1B USD
Have any thoughts about
Veracyte Inc?
Write Note

Intrinsic Value

The intrinsic value of one VCYT stock under the Base Case scenario is 17.18 USD. Compared to the current market price of 39.59 USD, Veracyte Inc is Overvalued by 57%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VCYT Intrinsic Value
17.18 USD
Overvaluation 57%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Veracyte Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VCYT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VCYT?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Veracyte Inc

Provide an overview of the primary business activities
of Veracyte Inc.

What unique competitive advantages
does Veracyte Inc hold over its rivals?

What risks and challenges
does Veracyte Inc face in the near future?

Has there been any significant insider trading activity
in Veracyte Inc recently?

Summarize the latest earnings call
of Veracyte Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Veracyte Inc.

Provide P/S
for Veracyte Inc.

Provide P/E
for Veracyte Inc.

Provide P/OCF
for Veracyte Inc.

Provide P/FCFE
for Veracyte Inc.

Provide P/B
for Veracyte Inc.

Provide EV/S
for Veracyte Inc.

Provide EV/GP
for Veracyte Inc.

Provide EV/EBITDA
for Veracyte Inc.

Provide EV/EBIT
for Veracyte Inc.

Provide EV/OCF
for Veracyte Inc.

Provide EV/FCFF
for Veracyte Inc.

Provide EV/IC
for Veracyte Inc.

Show me price targets
for Veracyte Inc made by professional analysts.

What are the Revenue projections
for Veracyte Inc?

How accurate were the past Revenue estimates
for Veracyte Inc?

What are the Net Income projections
for Veracyte Inc?

How accurate were the past Net Income estimates
for Veracyte Inc?

What are the EPS projections
for Veracyte Inc?

How accurate were the past EPS estimates
for Veracyte Inc?

What are the EBIT projections
for Veracyte Inc?

How accurate were the past EBIT estimates
for Veracyte Inc?

Compare the revenue forecasts
for Veracyte Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Veracyte Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Veracyte Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Veracyte Inc compared to its peers.

Compare the P/E ratios
of Veracyte Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Veracyte Inc with its peers.

Analyze the financial leverage
of Veracyte Inc compared to its main competitors.

Show all profitability ratios
for Veracyte Inc.

Provide ROE
for Veracyte Inc.

Provide ROA
for Veracyte Inc.

Provide ROIC
for Veracyte Inc.

Provide ROCE
for Veracyte Inc.

Provide Gross Margin
for Veracyte Inc.

Provide Operating Margin
for Veracyte Inc.

Provide Net Margin
for Veracyte Inc.

Provide FCF Margin
for Veracyte Inc.

Show all solvency ratios
for Veracyte Inc.

Provide D/E Ratio
for Veracyte Inc.

Provide D/A Ratio
for Veracyte Inc.

Provide Interest Coverage Ratio
for Veracyte Inc.

Provide Altman Z-Score Ratio
for Veracyte Inc.

Provide Quick Ratio
for Veracyte Inc.

Provide Current Ratio
for Veracyte Inc.

Provide Cash Ratio
for Veracyte Inc.

What is the historical Revenue growth
over the last 5 years for Veracyte Inc?

What is the historical Net Income growth
over the last 5 years for Veracyte Inc?

What is the current Free Cash Flow
of Veracyte Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Veracyte Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Veracyte Inc

Current Assets 356.9m
Cash & Short-Term Investments 274.1m
Receivables 48.8m
Other Current Assets 34m
Non-Current Assets 918.2m
PP&E 38.2m
Intangibles 871m
Other Non-Current Assets 9m
Current Liabilities 70.3m
Accounts Payable 9.7m
Accrued Liabilities 51.2m
Other Current Liabilities 9.5m
Non-Current Liabilities 28.7m
Long-Term Debt 100k
Other Non-Current Liabilities 28.6m
Efficiency

Earnings Waterfall
Veracyte Inc

Revenue
425.3m USD
Cost of Revenue
-134.2m USD
Gross Profit
291.1m USD
Operating Expenses
-282m USD
Operating Income
9.1m USD
Other Expenses
-18.4m USD
Net Income
-9.3m USD

Free Cash Flow Analysis
Veracyte Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Veracyte reported a strong Q3 performance, achieving $115.9 million in revenue, a 29% year-over-year increase, driven by a 34% rise in testing revenue. Notably, Decipher and Afirma tests saw impressive gains, with Decipher testing volumes up 36%. The company raised its 2024 revenue guidance to $442-$445 million from a previous range of $432-$438 million. Despite anticipated headwinds from the Envisia portfolio, testing revenue growth is expected to continue robustly into 2025. Adjusted EBITDA margins approached 24%, with expectations to maintain a sustainable 25% margin moving forward.

What is Earnings Call?
Fundamental Scores

VCYT Profitability Score
Profitability Due Diligence

Veracyte Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Positive Revenue Growth Forecast
46/100
Profitability
Score

Veracyte Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

VCYT Solvency Score
Solvency Due Diligence

Veracyte Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Veracyte Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VCYT Price Targets Summary
Veracyte Inc

Wall Street analysts forecast VCYT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VCYT is 43.86 USD with a low forecast of 28.28 USD and a high forecast of 52.5 USD.

Lowest
Price Target
28.28 USD
29% Downside
Average
Price Target
43.86 USD
11% Upside
Highest
Price Target
52.5 USD
33% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VCYT?

Click here to dive deeper.

Dividends

Veracyte Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VCYT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VCYT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Veracyte Inc Logo
Veracyte Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3B USD

Dividend Yield

0%

Description

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 761 full-time employees. The company went IPO on 2013-10-30. The firm offers customized biomarker testing and analytical services. The company offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. The company offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. The company also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Contact

CALIFORNIA
South San Francisco
6000 Shoreline Ct Ste 300
+16502436300.0
www.veracyte.com

IPO

2013-10-30

Employees

761

Officers

CEO & Director
Mr. Marc A. Stapley
Executive VP & CFO
Ms. Rebecca Chambers
Chief Scientific & Medical Officer
Dr. Phillip G. Febbo M.D.
Executive VP, General Counsel & Chief People Officer
Ms. Annie McGuire
Chief Commercial Officer for CLIA Business
Dr. John Leite Ph.D.
VP & Chief Accounting Officer
Mr. Jonathan Wygant
Show More
Senior VP & Chief Information Officer
Mr. Steven French
Senior Vice President of Corporate Marketing, Communications & Commercial Operations
Ms. Karen Possemato
Executive VP & Chief Business Officer
Mr. Robert Brainin
Senior Vice President
Ms. Corinne Danan
Show Less

See Also

Discover More
What is the Intrinsic Value of one VCYT stock?

The intrinsic value of one VCYT stock under the Base Case scenario is 17.18 USD.

Is VCYT stock undervalued or overvalued?

Compared to the current market price of 39.59 USD, Veracyte Inc is Overvalued by 57%.

Back to Top